- Home
- XYL vs GH Comparison
XYL vs GH Comparison
Compare XYL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XYL | GH |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.0B | 22.9B |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | XYL | GH |
|---|---|---|
| Price | $108.38 | $176.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $152.50 | $119.79 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 7.40 | 6.74 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $9,035,000,000.00 | $982,021,000.00 |
| Revenue This Year | $2.79 | $33.30 |
| Revenue Next Year | $4.49 | $28.27 |
| P/E Ratio | $56.58 | ★ N/A |
| Revenue Growth | 5.52 | ★ 32.88 |
| 52 Week Low | $105.29 | $53.40 |
| 52 Week High | $154.27 | $176.58 |
Technical Indicators
Market Signals| Indicator | XYL | GH |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 62.58 |
| Support Level | $106.01 | $153.88 |
| Resistance Level | $125.73 | N/A |
| Average True Range (ATR) | 2.53 | 8.60 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 22.09 | 85.57 |
Price Performance
Historical ComparisonAbout XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.